Genetic Leap, a leading AI-driven techbio company, has partnered with Eli Lilly and Company to develop RNA-targeted therapeutics. Building on a successful pilot, the collaboration will leverage Genetic Leap's advanced AI platform to create oligonucleotide drugs targeting RNA, focusing on critical therapeutic areas selected by Lilly. RNA, which regulates key biological processes, holds great promise for treating diseases that have been difficult to address with conventional drugs. However, targeting RNA has historically been challenging, and Genetic Leap’s AI platform is revolutionizing this approach.
"We are excited to collaborate with Lilly, sharing their dedication to advancing RNA medicines," said Dr. Bertrand Adanve, CEO and founder of Genetic Leap. "Our platform is designed to accelerate the development of life-saving treatments, and this partnership brings us closer to achieving that goal."
Under the agreement, Genetic Leap will receive up to $409 million in payments and tiered royalties based on development milestones.